<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">38568321</PMID><DateCompleted><Year>2024</Year><Month>04</Month><Day>12</Day></DateCompleted><DateRevised><Year>2024</Year><Month>07</Month><Day>14</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1534-6315</ISSN><JournalIssue CitedMedium="Internet"><Volume>24</Volume><Issue>4</Issue><PubDate><Year>2024</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Current allergy and asthma reports</Title><ISOAbbreviation>Curr Allergy Asthma Rep</ISOAbbreviation></Journal><ArticleTitle>What the SARS-CoV-2 Pandemic Has Taught Us About Immunosuppression, Vaccinations, and Immune Dysregulation: The Rheumatology Experience.</ArticleTitle><Pagination><StartPage>221</StartPage><EndPage>232</EndPage><MedlinePgn>221-232</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s11882-024-01139-9</ELocationID><Abstract><AbstractText Label="PURPOSE OF REVIEW">This review reflects on the impact of the COVID-19 pandemic on the field of rheumatology, emphasizing resulting insights related to the risks of viral infections in immunosuppressed patients, vaccine immunogenicity in immunocompromised patients, and immune dysregulation in the setting of viral infection.</AbstractText><AbstractText Label="RECENT FINDINGS">During the pandemic, global patient registries provided real-time insights into the risk factors associated with severe COVID-19 outcomes in rheumatology patients. Updated evidence-based recommendations from the American College of Rheumatology (ACR) guided rheumatology practice&#xa0;during a time of considerable&#xa0;uncertainty. Studies on COVID-19 vaccines in immunocompromised populations enhanced our&#xa0;understanding of specific immunosuppressive therapies on vaccine efficacy. The immune dysregulation seen in severe COVID-19 underscored a role for immunomodulation in this and other severe infections. Furthermore, novel post-infectious conditions, namely multisystem inflammatory syndrome in children (MIS-C) and Long COVID, reshaped our understanding of post-viral syndromes and revealed novel pathological mechanisms. Lessons from the COVID-19 pandemic demonstrate the power of collaborative research. The scientific revelations from this dreadful time will, nonetheless, benefit the practice of rheumatology for years to come.</AbstractText><CopyrightInformation>&#xa9; 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Jiang</LastName><ForeName>Yike</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Division of Pediatric Rheumatology, Department of Pediatrics, Duke University School of Medicine, Durham, NC, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sadun</LastName><ForeName>Rebecca E</ForeName><Initials>RE</Initials><AffiliationInfo><Affiliation>Division of Pediatric Rheumatology, Department of Pediatrics, Duke University School of Medicine, Durham, NC, USA. rebecca.sadun@duke.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Rheumatology and Immunology, Department of Medicine, Duke University School of Medicine, Durham, NC, USA. rebecca.sadun@duke.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>T32 HD094671</GrantID><Acronym>HD</Acronym><Agency>NICHD NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>04</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Curr Allergy Asthma Rep</MedlineTA><NlmUniqueID>101096440</NlmUniqueID><ISSNLinking>1529-7322</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000086663">COVID-19 Vaccines</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Disease" UI="C000705967">pediatric multisystem inflammatory disease, COVID-19 related</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012219" MajorTopicYN="Y">Rheumatology</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086663" MajorTopicYN="N">COVID-19 Vaccines</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007165" MajorTopicYN="N">Immunosuppression Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014611" MajorTopicYN="N">Vaccination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018746" MajorTopicYN="Y">Systemic Inflammatory Response Syndrome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Immune dysregulation</Keyword><Keyword MajorTopicYN="N">Immunosuppression</Keyword><Keyword MajorTopicYN="N">Pandemic</Keyword><Keyword MajorTopicYN="N">Rheumatology</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">Vaccines</Keyword></KeywordList><CoiStatement><b>Conflict of interest.</b> RS served on the ACR COVID-19 Vaccine Guidelines Task Force.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>2</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>4</Month><Day>12</Day><Hour>6</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>4</Month><Day>3</Day><Hour>12</Hour><Minute>50</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>4</Month><Day>3</Day><Hour>11</Hour><Minute>9</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>7</Month><Day>13</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38568321</ArticleId><ArticleId IdType="mid">NIHMS1999753</ArticleId><ArticleId IdType="pmc">PMC11245734</ArticleId><ArticleId IdType="doi">10.1007/s11882-024-01139-9</ArticleId><ArticleId IdType="pii">10.1007/s11882-024-01139-9</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Robinson PC, Yazdany J (2020) The COVID-19 Global Rheumatology Alliance: collecting data in a pandemic. Nat Rev Rheumatol 2020 166 16:293&#x2013;294</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7117553</ArticleId><ArticleId IdType="pubmed">32242121</ArticleId></ArticleIdList></Reference><Reference><Citation>Gianfrancesco M, Hyrich KL, Al-Adely S, et al. (2020) Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: Data from the COVID-19 Global Rheumatology Alliance physician-reported registry. Ann Rheum Dis 79:859&#x2013;866</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7299648</ArticleId><ArticleId IdType="pubmed">32471903</ArticleId></ArticleIdList></Reference><Reference><Citation>Strangfeld A, Sch&#xe4;fer M, Gianfrancesco MA, et al. (2021) Factors associated with COVID-19-related death in people with rheumatic diseases: Results from the COVID-19 Global Rheumatology Alliance physician-reported registry. Ann Rheum Dis 80:930&#x2013;942</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7843211</ArticleId><ArticleId IdType="pubmed">33504483</ArticleId></ArticleIdList></Reference><Reference><Citation>Kearsley-Fleet L, Chang ML, Lawson-Tovey S, et al. (2022) Outcomes of SARS-CoV-2 infection among children and young people with pre-existing rheumatic and musculoskeletal diseases. Ann Rheum Dis 81:998&#x2013;1005</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8977459</ArticleId><ArticleId IdType="pubmed">35338032</ArticleId></ArticleIdList></Reference><Reference><Citation>D&#x2019;Silva KM, Wallace ZS (2021) COVID-19 and rheumatoid arthritis. Curr Opin Rheumatol 33:255&#x2013;261</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8784188</ArticleId><ArticleId IdType="pubmed">33625043</ArticleId></ArticleIdList></Reference><Reference><Citation>Mikuls TR, Johnson SR, Fraenkel L, et al. (2020) American College of Rheumatology Guidance for the Management of Rheumatic Disease in Adult Patients During the COVID-19 Pandemic: Version 1. Arthritis Rheumatol (Hoboken, NJ) 72:1241&#x2013;1251</Citation><ArticleIdList><ArticleId IdType="pubmed">32349183</ArticleId></ArticleIdList></Reference><Reference><Citation>Mikuls TR, Johnson SR, Fraenkel L, et al. (2020) American College of Rheumatology Guidance for the Management of Rheumatic Disease in Adult Patients During the COVID-19 Pandemic: Version 2. Arthritis Rheumatol (Hoboken, NJ) 72:e1&#x2013;e12</Citation><ArticleIdList><ArticleId IdType="pubmed">32734689</ArticleId></ArticleIdList></Reference><Reference><Citation>Mikuls TR, Johnson SR, Fraenkel L, et al. (2021) American College of Rheumatology Guidance for the Management of Rheumatic Disease in Adult Patients During the COVID-19 Pandemic: Version 3. Arthritis Rheumatol (Hoboken, NJ) 73:e1&#x2013;e12</Citation><ArticleIdList><ArticleId IdType="pubmed">33277981</ArticleId></ArticleIdList></Reference><Reference><Citation>Wahezi DM, Lo MS, Rubinstein TB, et al. (2020) American College of Rheumatology Guidance for the Management of Pediatric Rheumatic Disease During the COVID-19 Pandemic: Version 1. Arthritis Rheumatol (Hoboken, NJ) 72:1809&#x2013;1819</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7404941</ArticleId><ArticleId IdType="pubmed">32705780</ArticleId></ArticleIdList></Reference><Reference><Citation>Wahezi DM, Lo MS, Rubinstein TB, et al. (2021) American College of Rheumatology Guidance for the Management of Pediatric Rheumatic Disease During the COVID-19 Pandemic: Version 2. Arthritis Rheumatol (Hoboken, NJ) 73:e46&#x2013;e59</Citation><ArticleIdList><ArticleId IdType="pubmed">34114365</ArticleId></ArticleIdList></Reference><Reference><Citation>Park JK, Lee MA, Lee EY, Song YW, Choi Y, Winthrop KL, Lee EB (2017) Effect of methotrexate discontinuation on efficacy of seasonal influenza vaccination in patients with rheumatoid arthritis: a randomised clinical trial. Ann Rheum Dis 76:1559&#x2013;1565</Citation><ArticleIdList><ArticleId IdType="pubmed">28468794</ArticleId></ArticleIdList></Reference><Reference><Citation>Park JK, Lee YJ, Shin K, Ha YJ, Lee EBY, Song YW, Choi Y, Winthrop KL, Lee EBY (2018) Impact of temporary methotrexate discontinuation for 2 weeks on immunogenicity of seasonal influenza vaccination in patients with rheumatoid arthritis: a randomised clinical trial. Ann Rheum Dis 77:898&#x2013;904</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5965360</ArticleId><ArticleId IdType="pubmed">29572291</ArticleId></ArticleIdList></Reference><Reference><Citation>Furer V, Eviatar T, Zisman D, et al. (2021) Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: A multicentre study. Ann Rheum Dis 80:1330&#x2013;1338</Citation><ArticleIdList><ArticleId IdType="pubmed">34127481</ArticleId></ArticleIdList></Reference><Reference><Citation>Furer V, Eviatar T, Freund T, et al. (2022) Immunogenicity induced by two and three doses of the BNT162b2 mRNA vaccine in patients with autoimmune inflammatory rheumatic diseases and immunocompetent controls: a longitudinal multicentre study. Ann Rheum Dis 81:1594&#x2013;1602</Citation><ArticleIdList><ArticleId IdType="pubmed">35868846</ArticleId></ArticleIdList></Reference><Reference><Citation>Jena A, Mishra S, Deepak P, Kumar-M P, Sharma A, Patel YI, Kennedy NA, Kim AHJ, Sharma V, Sebastian S (2022) Response to SARS-CoV-2 vaccination in immune mediated inflammatory diseases: Systematic review and meta-analysis. Autoimmun Rev 21:102927.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8404391</ArticleId><ArticleId IdType="pubmed">34474172</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee ARY Bin, Wong SY, Chai LYA, et al. (2022) Efficacy of covid-19 vaccines in immunocompromised patients: systematic review and meta-analysis. BMJ 376:e068632.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8889026</ArticleId><ArticleId IdType="pubmed">35236664</ArticleId></ArticleIdList></Reference><Reference><Citation>Wieske L, van Dam KPJ, Steenhuis M, et al. (2022) Humoral responses after second and third SARS-CoV-2 vaccination in patients with immune-mediated inflammatory disorders on immunosuppressants: a cohort study. Lancet Rheumatol 4:e338&#x2013;e350</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8930018</ArticleId><ArticleId IdType="pubmed">35317410</ArticleId></ArticleIdList></Reference><Reference><Citation>Heshin-Bekenstein M, Ziv A, Toplak N, et al. (2023) Safety and Immunogenicity Following the Second and Third Doses of the BNT162b2 mRNA COVID-19 Vaccine in Adolescents with Juvenile-Onset Autoimmune Inflammatory Rheumatic Diseases: A Prospective Multicentre Study. Vaccines 11:819.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10145688</ArticleId><ArticleId IdType="pubmed">37112731</ArticleId></ArticleIdList></Reference><Reference><Citation>Hall VG, Ferreira VH, Ku T, et al. (2021) Randomized Trial of a Third Dose of mRNA-1273 Vaccine in Transplant Recipients. N Engl J Med 385:1244&#x2013;1246</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8385563</ArticleId><ArticleId IdType="pubmed">34379917</ArticleId></ArticleIdList></Reference><Reference><Citation>Ku JH, Sy LS, Qian L, et al. (2023) Vaccine effectiveness of the mRNA-1273 3-dose primary series against COVID-19 in an immunocompromised population: A prospective observational cohort study. Vaccine 41:3636&#x2013;3646</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10154542</ArticleId><ArticleId IdType="pubmed">37173268</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonelli MM, Mrak D, Perkmann T, Haslacher H, Aletaha D (2021) SARS-CoV-2 vaccination in rituximab-treated patients: Evidence for impaired humoral but inducible cellular immune response. Ann Rheum Dis 80:1355&#x2013;1356</Citation><ArticleIdList><ArticleId IdType="pubmed">33958323</ArticleId></ArticleIdList></Reference><Reference><Citation>Bass AR, Chakravarty E, Akl EA, et al. (2023) 2022 American College of Rheumatology Guideline for Vaccinations in Patients With Rheumatic and Musculoskeletal Diseases. Arthritis Care Res 75:449&#x2013;464</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10291822</ArticleId><ArticleId IdType="pubmed">36597813</ArticleId></ArticleIdList></Reference><Reference><Citation>Curtis JR, Johnson SR, Anthony DD, et al. (2021) American College of Rheumatology Guidance for COVID-19 Vaccination in Patients With Rheumatic and Musculoskeletal Diseases: Version 1. Arthritis Rheumatol (Hoboken, NJ) 73:1093&#x2013;1107</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8250724</ArticleId><ArticleId IdType="pubmed">33728796</ArticleId></ArticleIdList></Reference><Reference><Citation>Curtis JR, Johnson SR, Anthony DD, et al. (2021) American College of Rheumatology Guidance for COVID-19 Vaccination in Patients With Rheumatic and Musculoskeletal Diseases: Version 2. Arthritis Rheumatol (Hoboken, NJ). 10.1002/ART.41877</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ART.41877</ArticleId><ArticleId IdType="pmc">PMC8427105</ArticleId><ArticleId IdType="pubmed">34128356</ArticleId></ArticleIdList></Reference><Reference><Citation>Curtis JR, Johnson SR, Anthony DD, et al. (2021) American College of Rheumatology Guidance for COVID-19 Vaccination in Patients With Rheumatic and Musculoskeletal Diseases: Version 3. Arthritis Rheumatol (Hoboken, NJ) 73:e60&#x2013;e75</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8426685</ArticleId><ArticleId IdType="pubmed">34346564</ArticleId></ArticleIdList></Reference><Reference><Citation>Curtis JR, Johnson SR, Anthony DD, et al. (2022) American College of Rheumatology Guidance for COVID-19 Vaccination in Patients With Rheumatic and Musculoskeletal Diseases: Version 4. Arthritis Rheumatol (Hoboken, NJ) 74:21&#x2013;e36</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9082483</ArticleId><ArticleId IdType="pubmed">35474640</ArticleId></ArticleIdList></Reference><Reference><Citation>Curtis JR, Johnson SR, Anthony DD, et al. (2023) American College of Rheumatology Guidance for COVID-19 Vaccination in Patients With Rheumatic and Musculoskeletal Diseases: Version 5. Arthritis Rheumatol (Hoboken, NJ) 75:E1&#x2013;E16</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9878068</ArticleId><ArticleId IdType="pubmed">36345691</ArticleId></ArticleIdList></Reference><Reference><Citation>Manson JJ, Crooks C, Naja M, et al. (2020) COVID-19-associated hyperinflammation and escalation of patient care: a retrospective longitudinal cohort study. Lancet Rheumatol 2:e594&#x2013;e602</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7442426</ArticleId><ArticleId IdType="pubmed">32864628</ArticleId></ArticleIdList></Reference><Reference><Citation>Otsuka R, Seino KI (2020) Macrophage activation syndrome and COVID-19. Inflamm Regen 40:1&#x2013;6</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7406680</ArticleId><ArticleId IdType="pubmed">32834892</ArticleId></ArticleIdList></Reference><Reference><Citation>P H, WS L, JR E, et al. (2021) Dexamethasone in Hospitalized Patients with Covid-19. N Engl J Med 384:693&#x2013;704</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7383595</ArticleId><ArticleId IdType="pubmed">32678530</ArticleId></ArticleIdList></Reference><Reference><Citation>Wagner C, Griesel M, Mikolajewska A, et al. (2021) Systemic corticosteroids for the treatment of COVID-19. Cochrane database Syst Rev. 10.1002/14651858.CD014963</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/14651858.CD014963</ArticleId><ArticleId IdType="pmc">PMC8406706</ArticleId><ArticleId IdType="pubmed">34396514</ArticleId></ArticleIdList></Reference><Reference><Citation>Marko M, Pawliczak R (2023) Assessment of the available therapeutic approaches for severe COVID-19: a meta-analysis of randomized controlled trials. Sci Rep 13:1&#x2013;11</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10564895</ArticleId><ArticleId IdType="pubmed">37816884</ArticleId></ArticleIdList></Reference><Reference><Citation>Leligdowicz A, Harhay MO, Calfee CS (2022) Immune Modulation in Sepsis, ARDS, and Covid-19 &#x2014; The Road Traveled and the Road Ahead. NEJM Evid. 10.1056/EVIDra2200118</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/EVIDra2200118</ArticleId><ArticleId IdType="pubmed">38319856</ArticleId></ArticleIdList></Reference><Reference><Citation>Karakike E, Giamarellos-Bourboulis EJ (2019) Macrophage activation-like syndrome: A distinct entity leading to early death in sepsis. Front Immunol 10:428603</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6365431</ArticleId><ArticleId IdType="pubmed">30766533</ArticleId></ArticleIdList></Reference><Reference><Citation>Casadevall A, Pirofski LA (2003) The damage-response framework of microbial pathogenesis. Nat Rev Microbiol 1:17&#x2013;24</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7097162</ArticleId><ArticleId IdType="pubmed">15040176</ArticleId></ArticleIdList></Reference><Reference><Citation>Balevic SJ, Dandachi D, Dixon D, Hoetelmans RMW, Bozzette S, McCarthy MW (2023) Infliximab Concentrations in Participants with Moderate to Severe COVID-19. J Clin Pharmacol 2023:1&#x2013;2</Citation><ArticleIdList><ArticleId IdType="pubmed">38031826</ArticleId></ArticleIdList></Reference><Reference><Citation>Bastard P, Rosen LB, Zhang Q, et al. (2020) Autoantibodies against type I IFNs in patients with life-threatening COVID-19. Science (80-). 10.1126/science.abd4585</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abd4585</ArticleId><ArticleId IdType="pmc">PMC7857397</ArticleId><ArticleId IdType="pubmed">32972996</ArticleId></ArticleIdList></Reference><Reference><Citation>Bastard P, Gervais A, Le Voyer T, et al. (2021) Autoantibodies neutralizing type I IFNs are present in ~4% of uninfected individuals over 70 years old and account for ~20% of COVID-19 deaths. Sci Immunol. 10.1126/sciimmunol.abl4340</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciimmunol.abl4340</ArticleId><ArticleId IdType="pmc">PMC8521484</ArticleId><ArticleId IdType="pubmed">34413139</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang EY, Mao T, Klein J, et al. (2021) Diverse functional autoantibodies in patients with COVID-19. Nature 595:283&#x2013;288</Citation><ArticleIdList><ArticleId IdType="pubmed">34010947</ArticleId></ArticleIdList></Reference><Reference><Citation>Riphagen S, Gomez X, Gonzalez-Martinez C, Wilkinson N, Theocharis P (2020) Hyperinflammatory shock in children during COVID-19 pandemic. Lancet 395:1607&#x2013;1608</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7204765</ArticleId><ArticleId IdType="pubmed">32386565</ArticleId></ArticleIdList></Reference><Reference><Citation>Verdoni L, Mazza A, Gervasoni A, Martelli L, Ruggeri M, Ciuffreda M, Bonanomi E, D&#x2019;Antiga L (2020) An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic: an observational cohort study. Lancet 395:1771&#x2013;1778</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7220177</ArticleId><ArticleId IdType="pubmed">32410760</ArticleId></ArticleIdList></Reference><Reference><Citation>Toubiana J, Poirault C, Corsia A, et al. (2020) Kawasaki-like multisystem inflammatory syndrome in children during the covid-19 pandemic in Paris, France: prospective observational study. BMJ 369:m2094.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7500538</ArticleId><ArticleId IdType="pubmed">32493739</ArticleId></ArticleIdList></Reference><Reference><Citation>Feldstein LR, Rose EB, Horwitz SM, et al. (2020) Multisystem Inflammatory Syndrome in U.S. Children and Adolescents. N Engl J Med. 10.1056/NEJMoa2021680</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2021680</ArticleId><ArticleId IdType="pmc">PMC7346765</ArticleId><ArticleId IdType="pubmed">32598831</ArticleId></ArticleIdList></Reference><Reference><Citation>Whittaker E, Bamford A, Kenny J, et al. (2020) Clinical Characteristics of 58 Children With a Pediatric Inflammatory Multisystem Syndrome Temporally Associated With SARS-CoV-2. JAMA 324:259&#x2013;269</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7281356</ArticleId><ArticleId IdType="pubmed">32511692</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharma C, Ganigara M, Galeotti C, Burns J, Berganza FM, Hayes DA, Singh-Grewal D, Bharath S, Sajjan S, Bayry J (2021) Multisystem inflammatory syndrome in children and Kawasaki disease: a critical comparison. Nat Rev Rheumatol 17:731&#x2013;748</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8554518</ArticleId><ArticleId IdType="pubmed">34716418</ArticleId></ArticleIdList></Reference><Reference><Citation>Feldstein LR, Tenforde MW, Friedman KG, et al. (2021) Characteristics and Outcomes of US Children and Adolescents with Multisystem Inflammatory Syndrome in Children (MIS-C) Compared with Severe Acute COVID-19. JAMA - J Am Med Assoc 325:1074&#x2013;1087</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7905703</ArticleId><ArticleId IdType="pubmed">33625505</ArticleId></ArticleIdList></Reference><Reference><Citation>Vogel TP, Top KA, Karatzios C, et al. (2021) Multisystem inflammatory syndrome in children and adults (MIS-C/A): Case definition &amp; guidelines for data collection, analysis, and presentation of immunization safety data. Vaccine 39:3037&#x2013;3049</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7904456</ArticleId><ArticleId IdType="pubmed">33640145</ArticleId></ArticleIdList></Reference><Reference><Citation>Albanji MH, Baghafar AA, Alghanmi YA, Shaaban MM, Alkashlan EA, Sende HH, Alzahrani MS, Filfilan NN (2023) Clinical Presentation and Management of Multisystem Inflammatory Syndrome in Children With COVID-19: A Systematic Review. Cureus. 10.7759/CUREUS.46918</Citation><ArticleIdList><ArticleId IdType="doi">10.7759/CUREUS.46918</ArticleId><ArticleId IdType="pmc">PMC10639140</ArticleId><ArticleId IdType="pubmed">37954764</ArticleId></ArticleIdList></Reference><Reference><Citation>Velusamy Y, Vivekanandan G, Romli MH, Shankar A, Karuppiah T, Yubbu P (2023) Safety and efficacy of pharmacological approaches available for multisystem inflammatory syndrome in children (MIS-C): a systematic review. Turk J Pediatr 65:719&#x2013;738</Citation><ArticleIdList><ArticleId IdType="pubmed">37853964</ArticleId></ArticleIdList></Reference><Reference><Citation>Sancho-Shimizu V, Brodin P, Cobat A, et al. (2021) SARS-CoV-2&#x2013;related MIS-C: A key to the viral and genetic causes of Kawasaki disease? J Exp Med. 10.1084/jem.20210446</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20210446</ArticleId><ArticleId IdType="pmc">PMC8080850</ArticleId><ArticleId IdType="pubmed">33904890</ArticleId></ArticleIdList></Reference><Reference><Citation>Cannon L, Campbell MJ, Wu EY (2023) Multisystemic Inflammatory Syndrome in Children and Kawasaki Disease: Parallels in Pathogenesis and Treatment. Curr Allergy Asthma Rep 23:341&#x2013;350</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10176315</ArticleId><ArticleId IdType="pubmed">37171672</ArticleId></ArticleIdList></Reference><Reference><Citation>Moreews M, Le Gouge K, Khaldi-Plassart S, et al. (2021) Polyclonal expansion of TCR Vbeta 21.3+ CD4+ and CD8+ T cells is a hallmark of Multisystem Inflammatory Syndrome in Children. Sci Immunol 6:25</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8815705</ArticleId><ArticleId IdType="pubmed">34035116</ArticleId></ArticleIdList></Reference><Reference><Citation>Porritt RA, Paschold L, Rivas MN, et al. (2021) HLA class I-associated expansion of TRBV11&#x2013;2 T cells in multisystem inflammatory syndrome in children. J Clin Invest. 10.1172/JCI146614</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI146614</ArticleId><ArticleId IdType="pmc">PMC8121516</ArticleId><ArticleId IdType="pubmed">33705359</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng MH, Zhang S, Porritt RA, Rivas MN, Paschold L, Willscher E, Binder M, Arditi M, Bahar I (2020) Superantigenic character of an insert unique to SARS-CoV-2 spike supported by skewed TCR repertoire in patients with hyperinflammation. Proc Natl Acad Sci U S A 117:25254&#x2013;25262</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7568239</ArticleId><ArticleId IdType="pubmed">32989130</ArticleId></ArticleIdList></Reference><Reference><Citation>Amormino C, Tedeschi V, Paldino G, Arcieri S, Fiorillo MT, Paiardini A, Tuosto L, Kunkl M (2022) SARS-CoV-2 Spike Does Not Possess Intrinsic Superantigen-like Inflammatory Activity. Cells 11:2526.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9406418</ArticleId><ArticleId IdType="pubmed">36010602</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee D, Le Pen J, Yatim A, et al. (2023) Inborn errors of OAS&#x2013;RNase L in SARS-CoV-2&#x2013;related multisystem inflammatory syndrome in children. Science (80-) 379:eabo3627.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10451000</ArticleId><ArticleId IdType="pubmed">36538032</ArticleId></ArticleIdList></Reference><Reference><Citation>Jain PN, Acosta S, Annapragada A, et al. (2022) Comparison of Laboratory and Hemodynamic Time Series Data Across Original, Alpha, and Delta Variants in Patients With Multisystem Inflammatory Syndrome in Children. Pediatr Crit Care Med 23:E372&#x2013;E381</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9345524</ArticleId><ArticleId IdType="pubmed">35507775</ArticleId></ArticleIdList></Reference><Reference><Citation>Levy N, Koppel JH, Kaplan O, Yechiam H, Shahar-Nissan K, Cohen NK, Shavit I (2022) Severity and Incidence of Multisystem Inflammatory Syndrome in Children during 3 SARS-CoV-2 Pandemic Waves in Israel. JAMA - J Am Med Assoc 327:2452&#x2013;2454</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9121298</ArticleId><ArticleId IdType="pubmed">35588048</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamad Saied M, van der Griend L, van Straalen JW, Wulffraat NM, Vastert S, Jansen MHA (2023) The protective effect of COVID-19 vaccines on developing multisystem inflammatory syndrome in children (MIS-C): a systematic literature review and meta-analysis. Pediatr Rheumatol 21:80</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10405572</ArticleId><ArticleId IdType="pubmed">37550719</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis HE, McCorkell L, Vogel JM, Topol EJ (2023) Long COVID: major findings, mechanisms and recommendations. Nat Rev Microbiol 21:133&#x2013;146</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9839201</ArticleId><ArticleId IdType="pubmed">36639608</ArticleId></ArticleIdList></Reference><Reference><Citation>Choutka J, Jansari V, Hornig M, Iwasaki A (2022) Unexplained post-acute infection syndromes. Nat Med 28:911&#x2013;923</Citation><ArticleIdList><ArticleId IdType="pubmed">35585196</ArticleId></ArticleIdList></Reference><Reference><Citation>Altmann DM, Whettlock EM, Liu S, Arachchillage DJ, Boyton RJ (2023) The immunology of long COVID. Nat Rev Immunol 23:618&#x2013;634</Citation><ArticleIdList><ArticleId IdType="pubmed">37433988</ArticleId></ArticleIdList></Reference><Reference><Citation>Calabrese C, Kirchner E, Calabrese LH (2022) Long COVID and rheumatology: Clinical, diagnostic, and therapeutic implications. Best Pract Res Clin Rheumatol 36:101794.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9641578</ArticleId><ArticleId IdType="pubmed">36369208</ArticleId></ArticleIdList></Reference><Reference><Citation>Clauw DJ, Calabrese L (2023) Rheumatology and Long COVID: Lessons from the study of fibromyalgia. Ann Rheum Dis 83:136&#x2013;138</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10850638</ArticleId><ArticleId IdType="pubmed">37230736</ArticleId></ArticleIdList></Reference><Reference><Citation>Gautret P, Lagier JC, Parola P, et al. (2020) Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents 56:105949.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7102549</ArticleId><ArticleId IdType="pubmed">32205204</ArticleId></ArticleIdList></Reference><Reference><Citation>Boulware DR, Pullen MF, Bangdiwala AS, et al. (2020) A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19. N Engl J Med 383:517&#x2013;525</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7289276</ArticleId><ArticleId IdType="pubmed">32492293</ArticleId></ArticleIdList></Reference><Reference><Citation>Self WH, Semler MW, Leither LM, et al. (2020) Effect of Hydroxychloroquine on Clinical Status at 14 Days in Hospitalized Patients with COVID-19: A Randomized Clinical Trial. JAMA - J Am Med Assoc 324:2165&#x2013;2176</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7653542</ArticleId><ArticleId IdType="pubmed">33165621</ArticleId></ArticleIdList></Reference><Reference><Citation>Mendel A, Bernatsky S, Askanase A, et al. (2021) Hydroxychloroquine shortages among patients with systemic lupus erythematosus during the COVID-19 pandemic: experience of the Systemic Lupus International Collaborating Clinics. Ann Rheum Dis 80:272&#x2013;274</Citation><ArticleIdList><ArticleId IdType="pubmed">32586918</ArticleId></ArticleIdList></Reference><Reference><Citation>State Action on Hydroxychloroquine and Chloroquine Access | Lupus Foundation of America. https://www.lupus.org/advocate/state-action-on-hydroxychloroquine-and-chloroquine-access.
Accessed
1 Feb 2024</Citation></Reference><Reference><Citation>Axfors C, Schmitt AM, Janiaud P, et al. (2021) Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials. Nat Commun 12:2349.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8050319</ArticleId><ArticleId IdType="pubmed">33859192</ArticleId></ArticleIdList></Reference><Reference><Citation>(2020) Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19. N Engl J Med 383:2030&#x2013;2040</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7556338</ArticleId><ArticleId IdType="pubmed">33031652</ArticleId></ArticleIdList></Reference><Reference><Citation>Pradelle A, Mainbourg S, Provencher S, Massy E, Grenet G, Lega J (2024) Biomedicine &amp; Pharmacotherapy Deaths induced by compassionate use of hydroxychloroquine during the first COVID-19 wave&#x202f;: an estimate. Biomed Pharmacother 171:116055.</Citation><ArticleIdList><ArticleId IdType="pubmed">38171239</ArticleId></ArticleIdList></Reference><Reference><Citation>Udupa A, Leverenz D, Balevic SJ, Sadun RE, Tarrant TK, Rogers JL (2021) Hydroxychloroquine and COVID-19: a Rheumatologist&#x2019;s Take on the Lessons Learned. Curr Allergy Asthma Rep 21:5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7818062</ArticleId><ArticleId IdType="pubmed">33475900</ArticleId></ArticleIdList></Reference><Reference><Citation>Balevic SJ, Hornik CP, Green TP, et al. (2020) Hydroxychloroquine in Patients with Rheumatic Disease Complicated by COVID-19: Clarifying Target Exposures and the Need for Clinical Trials. J Rheumatol 47:1424&#x2013;1430</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7655510</ArticleId><ArticleId IdType="pubmed">32393664</ArticleId></ArticleIdList></Reference><Reference><Citation>Desmarais J, Rosenbaum JT, Costenbader KH, et al. (2021) American College of Rheumatology White Paper on Antimalarial Cardiac Toxicity. Arthritis Rheumatol 73:2151&#x2013;2160</Citation><ArticleIdList><ArticleId IdType="pubmed">34697918</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>